News | July 16, 2025
Waters, BD biosciences unit agree to $17.5 billion merger
The transaction, approved by both companies' boards of directors, is expected to close by the end of the first quarter of 2026
The transaction, approved by both companies' boards of directors, is expected to close by the end of the first quarter of 2026
The agreement includes plans for distribution, technology transfer, local manufacturing, new pharmaceutical product development
Capricor’s BLA for Deramiocel received Priority Review in March 2025
Baxdrostat demonstrated a statistically significant and clinically meaningful reduction of systolic blood pressure compared with placebo
In collaboration with the Gates Foundation, Merck advances MK-8527 pre-exposure prophylaxis (PrEP) clinical trials globally
This year, 40 women students are participating, selected through a rigorous process evaluating academic merit, research interest, and socio-economic background
The Medical Countermeasures Strategy focuses on strengthening the EU’s preparedness for health crises
The UK authorization is based on positive results from the Phase III OASIS-1, -2, and -3 trials
Xtandi is approved in over 80 countries, including the U.S., EU, and Japan
India’s fertility rate has dropped to 1.9, below the replacement level of 2.1
Subscribe To Our Newsletter & Stay Updated
